Treatment of experimental Coxsackie B-3 viral myocarditis with Astragalus membranaceus in mice.
A murine model system for observing the effect of Astragalus Membranaceus (AM) on experimental myocarditis caused by Coxsackie B-3 virus (CB3V) was developed in 4-week-old male BALB/C mice. Gross, histopathologic and ultrastructural examinations of the infected-AM treated group showed that the severity and involved area of the myocardial lesions became milder and smaller than those in the infected-NS treated mice. The total lesion area, and the total lesion area/total myocardial area examined (%) and virus titer in the former group were also smaller and lower than those in the latter group. The results suggest that AM is effective in the inhibition of Coxsackie B virus propagation and protection of myocardium in mouse myocarditis.
Yang
Y Z
YZ
Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Shanghai Medical University.
Jin
P Y
PY
Guo
Q
Q
Wu
W Z
WZ
Pu
S Y
SY
Chen
H Z
HZ
Yang
J H
JH
Wang
K Q
KQ
Shi
J Y
JY
Gong
Z X
ZX
D000818:Animals; D027885:Astragalus propinquus; D003384:Coxsackievirus Infections; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D029822:Enterovirus B, Human; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009205:Myocarditis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
D004365:Drugs, Chinese Herbal